NYSE:PFE
Pfizer Inc (PFE)
30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Financials 
Technical Analysis 0
DON'T BUY
Companies like Pfizer and Merck have been coming apart for quite awhile. Growth rate has gone from 30% to low single digits. When this happens, the P/E has to contract. There are more sellers than buyers. One of the few that is doing better is Schering AG. Growth rate is accelerating and have a good line up of drugs.
biotechnologypharmaceutical
TOP PICK
Of all the drug companies put together, this company has the strongest pipe line. This is a mispriced asset. When you lok at the earnings, the balance sheet and where interest rates are, it's worth $50.
Brian Acker, CAOwned
biotechnologypharmaceutical
TOP PICK
Merck had to pull their rheumatoid arthritis drug. Pfizer's drug is somewhat similar which caused investors to sell. FDA says it is a safe drug, so the stock is at a good price.
John Sinkins, CFAOwned
biotechnologypharmaceutical
BUY
Offers reasonable opportunity here, but could be a long go before there are signs of recovery. Cheap. Long term concern is possible pricing controls.
Laura WallaceOwned
biotechnologypharmaceutical
BUY
The big block buster drugs are starting to face generic competition. Very cheap, but the market is worried about nothing being on the horizon for 2005/2006. Under $30 is a good price. Be willing to sit and wait. A great story.
John ZechnerOwned
biotechnologypharmaceutical
TOP PICK
Trading close to a 52 week low. Trading at about 11.5 X next year's earnings. A contrarian pick when looked at with the US$. A first class company. Have about $20 billion in net free cash flow.
Bob StodgellOwned
biotechnologypharmaceutical
DON'T BUY
An excellent company, but a poor stock. The whole pharmaceutical sector has been under pressure for 2/3 years.
Ian NakamotoOwned
biotechnologypharmaceutical
TOP PICK
30% discount between their model price and current stock price.
Brian Acker, CAOwned
biotechnologypharmaceutical
TOP PICK
Has been beaten up. Has all the good things going for it according to analysts. Strong cash flow.
Robert StovallOwned
biotechnologypharmaceutical
HOLD
Has had a very disappointing performance. Big pharmas have some issues facing them with regards to generic drugs. An extremely good company. Ran into problems because of their recall of Vioxx.
Laura WallaceOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
